<DOC>
	<DOCNO>NCT01419691</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness auranofin treat patient chronic lymphocytic leukemia ( CLL ) , small lymphocytic lymphoma ( SLL ) , prolymphocytic lymphoma ( PLL ) .</brief_summary>
	<brief_title>Phase I II Study Auranofin Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Auranofin</mesh_term>
	<criteria>histologically confirm Bcell chronic lymphocytic leukemia ( CLL ) , small lymphocytic lymphoma ( SLL ) , prolymphocytic leukemia arise CLL/SLL Richter 's transformation accord WHO criteria require therapy base 2008 revised IWCLL criterion . Relapsed refractory disease receive least 1 prior therapy CLL At least 18 year old ; ECOG status 1 le ; life expectancy 2 month great Adequate organ marrow function ( total bilirubin le 1.5x IULN ; ALT le 2x IULN ; serum creatinine le 1.5x ULN ) chemotherapy , radiotherapy immunotherapy within 4 week prior enter study recover AEs due agent administer 4 week prior receive investigational agent know second malignancy limit survival less 2 year know HIV positive uncontrolled intercurrent illness pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>auranofin</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>CLL</keyword>
	<keyword>SLL</keyword>
	<keyword>PLL</keyword>
</DOC>